Trial site
St. Luke's University Health Network
Bethlehem, Pennsylvania 18015, United StatesNot linked to an institution yet
- 19running trials
- 4closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 2/33 trials
- Phase 12 trials
- Phase 21 trial
- Phase 41 trial
- Status
- Active, not recruiting10 trials
- Recruiting9 trials
- Completed3 trials
- Terminated1 trial
- Lead sponsor
- Hoffmann-La Roche4 trials
- Bristol-Myers Squibb2 trials
- Medtronic2 trials
- United Therapeutics2 trials
- Actuate Therapeutics Inc.1 trial
- and 12 more
Running trials
Recruiting
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
NCT07310420· Phase 1· TerSera Therapeutics LLC· Source
Contact: Maria Hafez, MD
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Contact: Maria Hafez (principal investigator)
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
NCT06909565· Phase 4· Duke University· Source
Contact: Kyle McFadden
Active, not recruiting
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· Phase 3· Genmab· Source
Recruiting
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421· United Therapeutics· Source
Contact: Douglas Corwin, MD
Recruiting
Nectero EAST System Clinical Study
NCT06001918· Phase 2/3· Nectero Medical, Inc.· Source
Contact: Jena Hagerty
Recruiting
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
NCT05489705· Bristol-Myers Squibb· Source
Contact: Jamshid Shirani, Site 0043
Recruiting
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
NCT05204888· Temple University· Source
Contact: Monica Hosler
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586010· Phase 3· Hoffmann-La Roche· Source
Recruiting
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
NCT04575935· Phase 3· M.D. Anderson Cancer Center· Source
Contact: Nicholas Taylor, MD
Active, not recruiting
Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)
NCT04496518· Medtronic· Source
Active, not recruiting
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
NCT03589339· Phase 1· Nanobiotix· Source
Active, not recruiting
9-ING-41 in Patients With Advanced Cancers
NCT03678883· Phase 2· Actuate Therapeutics Inc.· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552· Phase 2/3· Hoffmann-La Roche· Source
Active, not recruiting
Personalized Therapy Study - Attain Stability Quad Post-Approval Study
NCT04024943· Medtronic· Source
Active, not recruiting
Heart Attack Research Program- Imaging Study
NCT02905357· NYU Langone Health· Source
Active, not recruiting
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986· Phase 3· AstraZeneca· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error